Cargando…

Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs

In dogs with non-resectable hepatic neoplasia, treatment options are limited. The objectives of this study were to describe the use of a novel drug-eluting embolic microsphere containing paclitaxel for use during transarterial chemoembolization (TACE), to compare results of liver-specific owner ques...

Descripción completa

Detalles Bibliográficos
Autores principales: Culp, William T. N., Johnson, Eric G., Giuffrida, Michelle A., Rebhun, Robert B., Cawthra, James K., Schwanz, Heidi A., Burton, Jenna H., Kent, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359553/
https://www.ncbi.nlm.nih.gov/pubmed/35939428
http://dx.doi.org/10.1371/journal.pone.0269941
_version_ 1784764164872339456
author Culp, William T. N.
Johnson, Eric G.
Giuffrida, Michelle A.
Rebhun, Robert B.
Cawthra, James K.
Schwanz, Heidi A.
Burton, Jenna H.
Kent, Michael S.
author_facet Culp, William T. N.
Johnson, Eric G.
Giuffrida, Michelle A.
Rebhun, Robert B.
Cawthra, James K.
Schwanz, Heidi A.
Burton, Jenna H.
Kent, Michael S.
author_sort Culp, William T. N.
collection PubMed
description In dogs with non-resectable hepatic neoplasia, treatment options are limited. The objectives of this study were to describe the use of a novel drug-eluting embolic microsphere containing paclitaxel for use during transarterial chemoembolization (TACE), to compare results of liver-specific owner questionnaires and tumor volume pre- and post-TACE, and to measure systemic paclitaxel concentration post-TACE. Client-owned dogs with non-resectable hepatic neoplasia were prospectively enrolled. All owners completed questionnaires validated for the assessment of subjective outcomes in dogs with cancer before the TACE procedure and approximately 4 weeks after the TACE procedure. A CT scan was performed before TACE and 1 month after TACE; results were compared. Blood samples were obtained at specified time points post-TACE to determine systemic paclitaxel concentrations. Seven dogs (median weight: 8.9 kg; range, 4.3–31 kg) were enrolled. TACE was successfully performed in all dogs, and no intra-procedural complications were encountered. Questionnaire scores improved significantly post-TACE. Among the 6 dogs for which full data were available, median pre-TACE tumor volume was 390 cc (range 152–1,484; interquartile range 231–1,139) and median post-TACE tumor volume was 203 cc (range 98–889; interquartile range 151–369), which was significantly (P = .028) lower. All 6 dogs had a reduction in volume at the post-TACE measurement. Mean percent change in tumor volume was -45.6% (95%CI -58.6 to -32.6%). The mean plasma paclitaxel concentration in canine blood peaked at 4 days post-TACE procedure and was 25.7 ng/mL (range = 3.09–110 ng/mL) Median survival time was 629 days (95%CI 18 to upper limit not reached). The use of a novel paclitaxel-eluting microsphere in this cohort of dogs successfully decreased tumor volume significantly after TACE and improved clinical signs. Future investigation into the use of TACE and other similar therapies is warranted due to the promising outcomes noted in this cohort.
format Online
Article
Text
id pubmed-9359553
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93595532022-08-10 Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs Culp, William T. N. Johnson, Eric G. Giuffrida, Michelle A. Rebhun, Robert B. Cawthra, James K. Schwanz, Heidi A. Burton, Jenna H. Kent, Michael S. PLoS One Research Article In dogs with non-resectable hepatic neoplasia, treatment options are limited. The objectives of this study were to describe the use of a novel drug-eluting embolic microsphere containing paclitaxel for use during transarterial chemoembolization (TACE), to compare results of liver-specific owner questionnaires and tumor volume pre- and post-TACE, and to measure systemic paclitaxel concentration post-TACE. Client-owned dogs with non-resectable hepatic neoplasia were prospectively enrolled. All owners completed questionnaires validated for the assessment of subjective outcomes in dogs with cancer before the TACE procedure and approximately 4 weeks after the TACE procedure. A CT scan was performed before TACE and 1 month after TACE; results were compared. Blood samples were obtained at specified time points post-TACE to determine systemic paclitaxel concentrations. Seven dogs (median weight: 8.9 kg; range, 4.3–31 kg) were enrolled. TACE was successfully performed in all dogs, and no intra-procedural complications were encountered. Questionnaire scores improved significantly post-TACE. Among the 6 dogs for which full data were available, median pre-TACE tumor volume was 390 cc (range 152–1,484; interquartile range 231–1,139) and median post-TACE tumor volume was 203 cc (range 98–889; interquartile range 151–369), which was significantly (P = .028) lower. All 6 dogs had a reduction in volume at the post-TACE measurement. Mean percent change in tumor volume was -45.6% (95%CI -58.6 to -32.6%). The mean plasma paclitaxel concentration in canine blood peaked at 4 days post-TACE procedure and was 25.7 ng/mL (range = 3.09–110 ng/mL) Median survival time was 629 days (95%CI 18 to upper limit not reached). The use of a novel paclitaxel-eluting microsphere in this cohort of dogs successfully decreased tumor volume significantly after TACE and improved clinical signs. Future investigation into the use of TACE and other similar therapies is warranted due to the promising outcomes noted in this cohort. Public Library of Science 2022-08-08 /pmc/articles/PMC9359553/ /pubmed/35939428 http://dx.doi.org/10.1371/journal.pone.0269941 Text en © 2022 Culp et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Culp, William T. N.
Johnson, Eric G.
Giuffrida, Michelle A.
Rebhun, Robert B.
Cawthra, James K.
Schwanz, Heidi A.
Burton, Jenna H.
Kent, Michael S.
Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
title Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
title_full Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
title_fullStr Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
title_full_unstemmed Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
title_short Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
title_sort evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359553/
https://www.ncbi.nlm.nih.gov/pubmed/35939428
http://dx.doi.org/10.1371/journal.pone.0269941
work_keys_str_mv AT culpwilliamtn evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT johnsonericg evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT giuffridamichellea evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT rebhunrobertb evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT cawthrajamesk evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT schwanzheidia evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT burtonjennah evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs
AT kentmichaels evaluationoftheuseofanovelbioabsorbablepolymerdrugelutingmicrospherefortransarterialembolizationofhepatocellularneoplasiaindogs